Media stories about C.R. Bard (NYSE:BCR) have trended somewhat positive recently, Accern reports. The research firm ranks the sentiment of news coverage by reviewing more than twenty million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. C.R. Bard earned a daily sentiment score of 0.22 on Accern’s scale. Accern also gave media coverage about the medical instruments supplier an impact score of 46.4823711773895 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the next few days.

These are some of the headlines that may have effected Accern Sentiment’s scoring:

Shares of C.R. Bard (BCR) traded up 0.16% during mid-day trading on Thursday, reaching $319.13. 449,022 shares of the company traded hands. The firm has a 50-day moving average price of $318.77 and a 200 day moving average price of $282.55. The firm has a market capitalization of $23.19 billion, a price-to-earnings ratio of 41.90 and a beta of 0.59. C.R. Bard has a 52 week low of $203.63 and a 52 week high of $323.27.

C.R. Bard (NYSE:BCR) last issued its quarterly earnings results on Thursday, July 27th. The medical instruments supplier reported $2.92 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $2.84 by $0.08. C.R. Bard had a net margin of 14.99% and a return on equity of 48.70%. The company had revenue of $979.70 million for the quarter, compared to the consensus estimate of $976.53 million. During the same quarter in the prior year, the company earned $2.54 EPS. C.R. Bard’s quarterly revenue was up 5.2% on a year-over-year basis. On average, analysts anticipate that C.R. Bard will post $11.84 earnings per share for the current year.

The firm also recently declared a quarterly dividend, which was paid on Friday, August 4th. Investors of record on Monday, July 24th were issued a $0.26 dividend. The ex-dividend date of this dividend was Thursday, July 20th. This represents a $1.04 annualized dividend and a yield of 0.33%. C.R. Bard’s dividend payout ratio (DPR) is presently 13.67%.

A number of analysts have recently commented on the stock. Zacks Investment Research upgraded shares of C.R. Bard from a “hold” rating to a “buy” rating and set a $351.00 price target for the company in a research note on Tuesday, June 13th. BMO Capital Markets lowered shares of C.R. Bard from an “outperform” rating to a “market perform” rating and set a $245.00 price target for the company. in a research note on Tuesday, April 25th. Morgan Stanley lowered shares of C.R. Bard from an “overweight” rating to an “equal weight” rating in a research note on Monday, April 24th. BidaskClub lowered shares of C.R. Bard from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, July 19th. Finally, Jefferies Group LLC reiterated a “hold” rating on shares of C.R. Bard in a research note on Thursday, August 3rd. One analyst has rated the stock with a sell rating, eight have given a hold rating, one has issued a buy rating and one has given a strong buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and a consensus price target of $285.67.

TRADEMARK VIOLATION NOTICE: “C.R. Bard (NYSE:BCR) Receives Daily Media Sentiment Score of 0.22” was originally posted by Watch List News and is owned by of Watch List News. If you are accessing this piece of content on another site, it was copied illegally and republished in violation of United States & international copyright laws. The legal version of this piece of content can be read at

About C.R. Bard

C. R. Bard, Inc (Bard) is engaged in designing, manufacturing, packaging, distribution and sale of medical, surgical, diagnostic and patient care devices. The Company operates through the manufacture and sale of medical devices segment. It sells a range of products to hospitals, individual healthcare professionals, extended care facilities and alternate site facilities on a global basis.

Insider Buying and Selling by Quarter for C.R. Bard (NYSE:BCR)

Receive News & Ratings for C.R. Bard Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for C.R. Bard Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.